Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

Expert opinion on pharmacotherapy - 1 Jun 2026

Robak Tadeusz

Abstract excerpt

INTRODUCTION: BTK inhibitors are divided into two groups based on their binding mechanism: covalent, irreversible (cBTKis), and non-covalent, reversible BTK inhibitors (ncBTKis). The covalent BTK inhibitors approved for use in CLL include the first-generation inhibitor ibutinib and second-generation BTK inhibitors, acalabrutinib and zanubrutinib. Non-covalent and reversible BTKs bind reversibly to BTK and remain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Antineoplastic Agents
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BTK gene

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Mutation

Share to Pyrazines

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 42212877
DOI: 10.1080/14656566.2026.2682839

Genes

BTK

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.PMID 42212877Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Targeting Bruton's Tyrosine Kinase in CLL.Semantic proximity Read ↗

Zanubrutinib: Coming of Age for BTK Inhibitors in the Treatment of Chronic Lymphocytic Leukemia?Semantic proximity Read ↗

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemiaSemantic proximity Read ↗

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read ↗

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.Semantic proximity Read ↗

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.